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ABSTRACT
Less than a third of adults patients with acute myeloid leukemia (AML) are 
cured by current treatments, emphasizing the need for new approaches to therapy. 
We previously demonstrated that besides playing a role in drug-resistant leukemia 
cell lines, multidrug resistance protein 4 (MRP4/ABCC4) regulates leukemia cell 
proliferation and differentiation through the endogenous MRP4/ABCC4 substrate, 
cAMP. Here, we studied the role of MRP4/ABCC4 in tumor progression in a mouse 
xenograft model and in leukemic stem cells (LSCs) differentiation. We found a 
decrease in the mitotic index and an increase in the apoptotic index associated with 
the inhibition of tumor growth when mice were treated with rolipram (PDE4 inhibitor) 
and/or probenecid (MRPs inhibitor). Genetic silencing and pharmacologic inhibition 
of MRP4 reduced tumor growth. Furthermore, MRP4 knockdown induced cell cycle 
arrest and apoptosis in vivo. Interestingly, when LSC population was isolated, we 
observed that increased cAMP levels and MRP4/ABCC4 blockade resulted in LSCs 
differentiation. Taken together, our findings show that MRP4/ABCC4 has a relevant 
role in tumor growth and apoptosis and in the eradication of LSCs, providing the basis 
for a novel promising target in AML therapy. 
INTRODUCTION 
Acute myeloid leukemia (AML) is a heterogeneous 
clonal disorder where early hematopoietic cells fail to 
differentiate and do not undergo programmed cell death 
or apoptosis. AML is most common in the elderly, but it 
represents 15-20% of childhood acute leukemias [1]. In 
the last decades, chemotherapy has been the treatment of 
choice for AML but one of the major complications is that 
the current drugs are highly toxic and poorly tolerated, 
especially by older patients [2]. Furthermore, despite 
the high-dose chemotherapy, only 20-30% of patients 
with AML are cured, emphasizing the need for new 
therapeutical approaches [3]. 
The study of multidrug resistance proteins (MRPs), 
also known as members of the C-family of ATP-binding 
cassette (ABC) drug transporters, was classically focused 
on their role in cancer chemotherapy, particularly on their 
ability to confer clinical drug resistance [4]. However, 
the pathophysiological actions of these proteins are 
quite diverse, and transport of cytotoxic xenobiotics as a 
defense mechanism appears not to be the only important 
evolutionarily conserved function. Moreover, while 
several members of the ABC family are established 
as drug transporters, others also mediate transport of 
intracellular substances that have relevant functions in 
cancer biology [5]. In particular, MRP4/ABCC4 is the 
main transporter for cAMP, a relevant signaling molecule 
that controls cellular proliferation, differentiation, and 
apoptosis, especially in hematopoietic development [6-8]. 
Interestingly, MRP4/ABCC4 expression decreases during 
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leukocyte differentiation, promoting cAMP accumulation 
in differentiated cells [9]. In accordance, comparison of 
different AML subtypes showed that the highest level of 
MRP4/ABCC4 is expressed in the least differentiated 
subtypes [10]. 
In recent years, emerging evidence suggests that 
leukemic stem cells (LSCs) lie at the heart of post-
treatment relapse and chemoresistance. Thus, the search 
for effective LSC-directed therapy by targeting their 
specific properties such as self-renewal, overexpressed 
cell-surface proteins or aberrant differentiation is a critical 
challenge [11]. In particular, the increasing recognition 
that molecules involved in stem cell differentiation have 
a key role in carcinogenesis prompts our investigation in 
this direction. Previous studies have shown that various 
ABC transporters are highly expressed in LSCs as part of 
their self-protection capabilities [12]. 
In the last years our research has been focused on 
the regulation of cAMP levels with potential implication 
in the differentiation and/or cytotoxicity of hematopoietic 
cancer cells. In this regard, we reported that MRP4/
ABCC4 regulates intracellular cAMP levels in AML 
cell lines and contributes to cell proliferation and 
differentiation [13]. Based on these findings, the aim of 
the present work was to advance into the knowledge of 
MRP4/ABCC4 as a potential new therapeutic target for 
AML. For this purpose, we evaluated the role of this 
transporter in tumor progression in a mouse xenograft 
model and in the temporal resolution of cAMP response 
in LSCs differentiation. Here, we show that MRP4/
ABCC4 blockade strongly reduced tumor growth inducing 
cell cycle arrest and apoptosis in vivo. In addition, we 
found that increased cAMP levels and MRP4/ABCC4 
inhibition resulted in LSCs differentiation. Altogether, 
these findings show that MRP4/ABCC4 has a relevant 
role in tumor growth and apoptosis and in the eradication 
of LSCs, providing the basis for a novel promising target 
in leukemia therapy.
RESULTS
Phosphodiesterase 4 (PDE4) and MRPs inhibition 
decrease tumor growth inducing cytostasis and 
apoptosis in an AML in vivo model
Cyclic AMP levels have been associated with 
leukemia cell proliferation. We have recently reported 
that intracellular cAMP accumulation induced by 
Figure 1: Effect of MRP and PDE4 inhibition on mouse AML tumor volume. Nude mice were subcutaneously injected 
with U937 AML cells. When tumors were palpable, animals (six per group) were treated with vehicle (control), rolipram (R,1.5 mg/kg), 
probenecid (P, 50 mg/kg), or in combination (R+P) for 16 days. (A) Growth curves. Tumors were measured every 2 or 3 days and volumes 
calculated as described in “Materials and methods”. (B) Representative picture of the dissected tumors of each group (left panel) and tumor 
volumes (right panel) at the end of the experiment. Data represent mean±SEM. **, p<0.01 vs. control. A representative experiment of the 
other two is plotted. 
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PDE4 and MRP inhibition significantly decreases cell 
proliferation in diverse AML cell lines [13]. Thus, to 
evaluate the effect of cAMP regulation on leukemia cell 
proliferation in vivo, a human AML model was established 
by subcutaneously injecting Swiss nu/nu mice with U937 
cells. When tumors were palpable, mice were treated 
with intraperitoneal injections of probenecid (MRP 
inhibitor, 50 mg/kg), rolipram (PDE4 inhibitor, 1.5 mg/
kg), probenecid+rolipram or with vehicle 5 times per week 
for 2 weeks. Tumors were measured 3 times per week and 
volumes calculated. Interestingly, all treatments showed 
inhibition of tumor growth, a significant smaller tumor 
volume was achieved in probenecid and/or rolipram-
treated animals as compared with vehicle-treated mice 
after 2 weeks (P<0.01; Figure 1A-B).
Next, the tumor morphology was evaluated in H&E-
stained sections, with emphasis on tissue organization as 
a whole (evaluated at low magnification), the presence 
of neo-vascularization (new, heterogeneous, one layer 
endothelial vessels), the cytological characteristics 
of tumor cells, mitosis and apoptosis. Control tumors 
exhibited a solid monomorphic sheet with no necrotic or 
hemorrhagic areas, while treated tumors showed variable 
necrotic areas (Figure 2A). A significant decrease in the 
mitotic index was observed in mice treated with rolipram, 
probenecid, and rolipram with probenecid. Moreover, the 
latter treatment was even more effective in decreasing 
the number of mitosis compared with mice treated with 
rolipram or probenecid alone (Figure 2B). In addition, as 
shown in Figure 2C, a significant increase in the apoptotic 
index was observed in mice treated with all compounds. 
Hence, the mitotic and apoptotic indexes correlated with 
the effect of PDE4 and/or MRPs inhibition on tumor 
growth. 
MRP4 knockdown decreases tumor growth in vivo
As MRP4 is the main transporter for cAMP and 
this signaling molecule has important implications in 
Figure 2: Tumor morphology and quantification of mitosis and apoptosis in rolipram or/and probenecid treated-mice. 
Tumors from mice treated with rolipram (R), probenecid (P), or both (R+P) were processed for histological evaluation. (A) Representative 
images of H&E-stained tumor slides are shown. Mitotic images (black arrows) and apoptosis (yellow arrows) are displayed in the H&E 
stained slides. The number of mitotic (B) and apoptotic (C) cells was counted in the H&E stained sections, using 600x magnification, by 
direct evaluation of 10 and 15 high power fields (HPF), respectively. The mean value ±SEM obtained in control slides was considered as 
100%. *, p<0.05; ***, p<0.001.
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hematopoietic cell proliferation we aimed to evaluate 
whether MRP4 played a role in vivo in AML tumor 
growth. Nude mice were injected with U937 cells 
expressing short hairpin RNA (shRNA) against MRP4 
(MRP4-shRNA) or scrambled, used as a control. The 
generation and characterization of these cells with 
stable MRP4-knockdown has been previously reported 
by us [13] and tested by western blot and cAMP assay 
just before mice injection (Supplementary Figure 1). 
In order to compare this molecular approach with the 
most effective pharmacological treatment (Figure 2), a 
third group of mice carrying U937-scramble tumor was 
treated with both rolipram and probenecid (1.5 mg/kg and 
50 mg/kg, respectively) 5 times per week for 2 weeks. 
Remarkably, silencing of MRP4 strongly reduced tumor 
growth likewise the pharmacological treatment (Figure 
3A-B). 
To provide further evidence that MRP4 knockdown 
was effective in vivo, following 2 weeks MRP4 
expression was assessed by western blot in scramble, 
rolipram+probenecid and MRP4-shRNA tumors. As 
expected, a significant reduction in MRP4 protein levels 
was observed in MRP4-shRNA tumors as compared with 
scramble tumors. However, MRP4 expression was similar 
in rolipram+probenecid and scramble tumors, although 
we have previously reported that rolipram and probenecid 
increase intracellular cAMP levels [13], (Figure 3C).
Figure 3: Effect of MRP4 knockdown on mouse AML tumor volume. Nude mice were subcutaneously injected with U937 
expressing shRNA against MRP4 (MRP4-shRNA) or scrambled shRNA as a control (scramble). A third group of mice, carrying U937-
scramble tumors, was treated with rolipram and probenecid (scramble R+P, 1.5 mg/kg and 50 mg/kg, respectively) (A) Growth curves. 
Tumors were measured every 2 or 3 days and volumes calculated as described in “Materials and methods”. (B) Representative picture of 
the dissected tumors of each group (left panel) and tumor volumes (right panel) at the end of the experiment. (C) Representative western 
blot of protein extracts from scramble, scramble R+P and MRP4-shRNA tumors using specific antibodies against MRP4/ABCC4 and α 
-tubulin (loading control). The band intensities in different western blots were quantified using ImageJ (US National Institutes of Health). 
Data represent mean±SEM. ***, p<0.001 vs. control. A representative experiment of the other two is plotted.
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MRP4 knockdown decreases the mitotic index 
and induces G1 phase arrest by reducing cyclin 
D1 and increasing p21Waf1/Cip1 expressions
 After two weeks, tumors were excised and their 
morphology evaluated in H&E-stained sections. MRP4-
shRNA tumors developed vast necrotic areas, and 
evident neo-vascularization; no significant histological 
differences were observed between this group and 
the rolipram+probenecid-treated mice (Figure 4A). 
Furthermore, tumors from MRP4-shRNA mice showed 
a significant decreased mitotic index as compared with 
control mice, although no differences were observed with 
mice treated with both rolipram and probenecid (Figure 
4B).
Next, we assessed in vivo the effect of 
silencing MRP4 or inhibiting MRPs and PDE4 on the 
expression of key regulators of G1 phase progression 
including cyclinD1 and p21Waf1/Cip1. As shown in 
Figure 4C, immunohistochemistry analysis revealed a 
decreased cyclin D1 expression in MRP4-shRNA and 
rolipram+probenecid tumors compared with the scramble 
shRNA. In accordance, the levels of p21 exhibited a 
dramatic up-regulation in both groups (Figure 4D). 
Collectively, these results indicate that MRP4 blockade 
or rolipram+probenecid treatment, triggers cytostasis by 
inducing G1 phase arrest. 
MRP4 knockdown induces apoptosis in vivo
Cyclic AMP plays a central role in several cellular 
processes like proliferation, differentiation and apoptosis 
[6,8]. The human U937 promonocytic leukemia cell line 
can be forced to differentiate into monocytes under the 
appropriate treatment [14]. In a previous paper, we reported 
that MRP pharmacological inhibition as well as specific 
MRP4 knockdown induced U937 cell differentiation by 
increasing cAMP intracellular levels [13]. Therefore, 
in the present study we evaluated cell differentiation in 
tumors from mice treated with rolipram and probenecid 
and with MRP4-shRNA. No significant differences 
were observed on the expression of the differentiation 
markers CD11b, CD14, CD88 (data not shown). As 
cAMP-elevating agents may trigger differentiation and/
or apoptosis, we next quantified apoptosis by TUNEL 
staining. Figure 5A depicts a complete field for tumors 
Figure 4: Effect of MRP4 knockdown on tumor morphology, mitotic index and cell cycle arrest. Tumors from scramble, 
rolipram+probenecid (scramble R+P) and MRP4-shRNA groups were processed for histological evaluation, immunohistochemistry and 
western blot. (A) Representative images of H&E-stained tumor slides are shown. Mitotic images (arrows) are displayed in the H&E 600x 
slides. (B) The number of mitotic cells was counted in the H&E stained sections, using 600x magnification, by direct evaluation of 10 high 
power fields (HPF). The mean value ±SEM obtained in control slides was considered as 100%. (C) Immunohistochemistry of paraffin-
embedded tumors was performed using an antibody against cyclin D1. Brown corresponds to the antibody signal and blue marks nuclei 
stained with hematoxilin. (D) Representative western blot of protein extracts from scramble, scramble R+P and MRP4-shRNA tumors 
using specific antibodies against p21 and α-tubulin (loading control). 
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from scramble, rolipram+probenecid and MRP4-shRNA 
groups. In both cases, the number of apoptotic cells was 
significantly higher than in the scramble shRNA control 
group (Figure 5A, right graph). 
Caspase-3 is a very important regulator of apoptosis 
in response to a variety of stimuli. In accordance with 
TUNEL results, the inhibition of MRP and PDE4 as 
well as MRP4 specific knockdown, induced caspase-3 
cleavage-mediated activation (Figure 5B). In line 
with these findings, an increased expression of Bax, a 
proapoptotic protein, was detected in the MRP4-shRNA 
and rolipram+probenecid tumors. However, while MRP4 
knockdown tumors presented a uniform staining, the 
rolipram+probenecid group exhibited heterogeneous 
stained sections. This difference observed in Bax 
expression correlates well with the different approaches 
used to inhibit MRP4 (Figure 5C). 
Taken together, these findings show that both 
pharmacological treatment and MRP4 knockdown induce 
apoptosis but not cell differentiation in tumors in vivo. 
MRP4 is expressed in isolated LSCs
Results so far indicate that MRP4 is involved in 
tumor growth and apoptosis, suggesting that MRP4 
might be a new target for AML treatment. Based on these 
observations and the increasing recognition that relapse of 
AML reflects the failure of current therapies to effectively 
target leukemic stem cells (LSCs), we aimed to isolate 
LSCs in the U937 AML cell line. However, in these cells 
the LSC population was less than 0.1%, supporting that 
the U937 cell line is not a good model to study LSCs (data 
not shown). It was recently reported that KG-1a, a human 
undifferentiated AML cell line, is a suitable cellular model 
to study LSCs [15]. Therefore, in order to confirm the 
presence and percentage of LSCs (CD34+CD38-) in the 
KG-1a cell line, cells were stained with a combination of 
CD34-PE and CD38-PECy5 antibodies and then analyzed 
by flow cytometry. Results showed that KG-1a cells 
contained more than 70% of CD34+CD38- cells (Figure 
6A, left panel). Then, CD34+CD38- and CD34+CD38+ 
populations (LSCs and non-LSCs, respectively) were 
sorted from the cell line using FACS. Post-sorting cell 
purity revealed that the LSCs-sorted population was 
99% pure (Figure 6A, right panel). Four sortings were 
Figure 5: Pro-apoptotic activity of MRP4 knockdown in AML in vivo tumors. (A) Left. Terminal deoxynucleotidyltransferase 
(TdT)-mediated dUTP digoxigenin nick-end labelling (TUNEL) of scramble, rolipram+probenecid (scramble R+P) and MRP4-shRNA 
tumors. Right. Quantification of apoptotic cells, stained cells by TUNEL, with respect to total cells per field. Data represent the mean±SEM. 
n=3 for each tumor type. **, p<0.01and ***, p<0.001vs. scramble. (B) Representative western blot of protein extracts from scramble, 
scramble R+P and MRP4-shRNA tumors using specific antibodies against caspase-3 and α -tubulin (loading control). Procaspase-3 (35 
KDa) and cleaved caspase-3 (20 KDa) are shown. (C) Immunohistochemistry of paraffin-embedded tumors was performed using an 
antibody against Bax. Brown corresponds to the antibody signal and blue marks nuclei stained with hematoxilin.
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performed and the percentage of LSCs was always higher 
than non-LSCs (68±9% vs 26±5%; p<0.01) (Figure 
6B). To further characterize the CD34+CD38- sorted 
population, cells were stained with CD123 antibody given 
that CD123 (IL-3 receptor α chain) is a unique marker 
for human AML stem cells [16]. As shown in Figure 6C, 
a high percentage of the CD34+CD38- sorted population 
expressed CD123. 
AML stem cells have been shown to express 
various ABC transporters conferring resistance to a broad 
spectrum of chemotherapeutic drugs [12]. In order to 
validate MRP4/ABCC4 as a new target for the eradication 
of LSCs, we assessed the presence of this transporter in 
the sorted populations. MRP4/ABCC4 protein expression 
in the CD34+CD38- population was shown by flow 
cytometry (Figure 6D). 
MRP4/ABCC4 inhibition results in LSCs 
differentiation
Since MRP4/ABCC4 is involved in the regulation 
of cAMP levels, which are critical for leukemic cell 
differentiation, we further analyzed its role in LSCs 
differentiation. First, in order to maintain the LSC 
population undifferentiated in culture we determined 
the optimal culture conditions. A marked increase in 
proliferation rate was observed in CD34+CD38- cells 
cultured in IMDM compared to the cells in GBGM, a 
medium developed for the culture of hematopoietic stem 
cells[17] . However, after 7 days in culture in IMDM, 
CD34+CD38- cells tended to differentiate into the 
CD34+CD38+ population, while in GBGM they retained 
their undifferentiated phenotype (Supplementary Figure 2). 
Subsequently, we employed GBGM to determine the effect 
of cAMP modulators and/or MRP4/ABCC4 inhibitor, on 
CD34+CD38- cells using non-cytotoxic concentrations 
of the compounds. LSCs differentiation was assessed by 
CD38 and CD11b expression in the presence of 10 μM 
forskolin (FK; direct adenylyl cyclase activator), 50 μM 
MK-571 (MK; MRP4/ABCC4 inhibitor), either alone or 
in combination, for 48 h. As shown in Figure 7A, FK or 
MK induced CD38 expression. Moreover, co-incubation 
with both agents yielded significantly higher levels of this 
marker.
To gain more insight into LSCs differentiation, the 
myelomonocytic lineage marker CD11b was evaluated. 
Neither FK nor MK alone induced expression of this 
differentiation marker in the LSC population. However, 
cells treated with both FK and MK enhanced CD11b 
surface expression (Figure 7B). 
Present findings indicate that MRP4/ABCC4 might 
be a new target for LSCs eradication in AML by inducing 
their differentiation. 
Figure 6: KG-1a cell line contains leukemic stem-like cells expressing MRP4/ABCC4. (A) Flow cytometry analysis of cell 
surface expression of CD34 and CD38 in KG-1a cells before (left panel) and after sorting using FACS (right panel). (B) The percentages 
of CD34+CD38-(LSCs) and CD34+CD38+ (non-LSCs) cells were obtained after independent sortings. **, p<0.01. Data represent the 
mean±SEM (n=4). (C) Histogram overlay shows CD123 expression in CD34+CD38- cells (black curve) versus IgG1-PE isotype control 
(filled gray curve). (D) Histogram overlay shows cell surface expression of MRP4/ABCC4 within CD34+CD38-cells (black curve) versus 
the unspecific control (filled gray curve). Data are from one experiment representative of three.
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DISCUSSION
The study of ABC transporters was classically 
focused on their role in cancer chemotherapy, particularly 
on their ability to confer resistance to a wide range of 
chemotherapeutic agents [4]. However, while several 
members of the ABC family are established as drug 
transporters, others also mediate transport of endogenous 
substances that have relevant functions in cancer biology 
[5]. A number of clinical studies have correlated ABC 
transporter levels with malignant progression and a more 
aggressive phenotype. In particular, current evidences 
suggest that MRP4/ABCC4 is implicated not only in 
chemotherapy resistance, but also in cancer biology. 
In this respect, recent studies have shown that MRP4/
ABCC4 is overexpressed in several solid tumors such as 
prostate cancer, non-small cell lung cancer, aggressive 
primary neuroblastoma, and pancreatic cancer [18-22]. 
Increased MRP4/ABCC4 levels have been significantly 
associated with poor clinical outcome in neuroblastoma. It 
has been reported that MRP4 is expressed in blast cells of 
patients with AML and higher levels of this protein were 
detected in the less differentiated FAB subtypes M0 and 
M1; however, its expression has no influence on treatment 
outcome using AraC [9,10]. Recently, frequent copy 
number alterations of MRP4/ABCC4 were observed in 
de novo AML and variable expression of this transporter 
was detected among AML subtypes from 155 pediatric 
patients [23]. In addition to cancer, this transporter appears 
to be involved in the development and progression of 
pulmonary arterial hypertension, a severe vascular disease 
[24]. Thus, this transporter has recently emerged as a new 
promising target for these pathologies. 
MRP4/ABCC4 has specificity for a wide range 
of endogenous substrates. It is the major cAMP efflux 
transporter, a cyclic nucleotide involved in the regulation 
of cellular proliferation, differentiation and apoptosis 
[25,26]. Indeed, previously we demonstrated that besides 
playing a role in drug-resistant leukemia cell lines, 
MRP4/ABCC4 regulates leukemia cell proliferation 
and differentiation through the endogenous MRP4/
ABCC4 substrate, cAMP [13]. Unlike other ABC family 
Figure 7: Treatment of LSCs with FK and MK results in LSCs differentiation. KG-1a cells were exposed to 10 µM forskolin 
(FK), 50 µM MK-571(MK) or FK+MK for 48 h. (A) Representative flow cytometry analysis of CD38 expression (left panel) and percentage 
of CD38 positive cells in the LSC population (right panel). (B) CD11b antigen expression in the LSC population. *, p<0.05; ***, p<0.001 
versus control. ###, p<0.001 versus FK+MK. Data represent mean±SEM (n=3).
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members, little is known about this transporter and its role 
in leukemia progression, independent of its drug efflux 
properties. To our knowledge, present findings provide 
for the first time strong evidence that MRP4/ABCC4 is 
involved in tumor growth, differentiation and/or apoptosis 
in AML. 
Leukemic stem cells (LSCs) are crucial in 
leukemia initiation, progression, metastasis and relapse. 
Therapeutic approaches targeting mature leukemic cells 
may clinically improve the disease, although they are 
unlikely curative if LSCs are not targeted or are resistant 
to the therapy. Hence, new treatments should be tested on 
this population. Tumors are the primary source for cancer 
stem cells (CSCs), although cancer cell lines are attractive 
alternative sources given that they are not contaminated 
with normal stem cells [27]. On the other hand, stem cells 
in tissues are usually in a very small number, which makes 
it rather difficult to identify and further to isolate them. 
In this study we detected LSCs (CD34+CD38-) in the 
undifferentiated AML cell line KG-1a and revealed that 
they represent approximately 70% of the cell population, 
whereas in other AML cell lines they are less than 1% and 
in AML patients around 0.01% to 0.09% [11,28]. Previous 
studies reported that LSCs isolated from the KG-1a cell 
line have LSC-specific features, including self-renewal 
capacity [15]. In accordance, the present study showed that 
the CD34+CD38- sorted population expresses CD123, a 
stem cell-specific marker in AML. These findings support 
that the KG-1a cell line is a suitable model to isolate and 
study LSCs.
The high expression of ABC transporters involved 
in the extrusion of chemotherapeutic compounds was 
proposed to be a major mechanism of drug resistance in 
LSCs [12]. Interestingly, when different AML subtypes 
were compared, the least differentiated subtypes expressed 
the highest level of MRP4/ABCC4 [10]. Moreover, 
mRNA of this transporter was previously detected in LSCs 
from untreated AML patients [12]. We found that MRP4/
ABCC4 is expressed at protein level in the CD34+CD38- 
KG-1a sorted population. Incomplete eradication of LSCs 
is likely to result in disease relapse and one approach to 
interfere with LSCs is to force them into differentiation. 
An example of the effectiveness of differentiating agents 
to eliminate CSCs is all-trans-retinoic acid that has been 
successfully used in promyelocytic AML3 subtype [29]. 
In addition, factors that increase cAMP levels augment 
the ability of this therapy to induce differentiation in 
blast cells [30]. Here, we evaluated differentiation in 
the LSC population by measuring the expression of the 
differentiation-specific antigens CD38 and CD11b. It is 
well known that the KG1a cell line fails to respond to 
several differentiating agents including phorbol esters, 
but in the present study when cAMP production was 
stimulated by forskolin, MRP4/ABCC4 inhibition induced 
CD38 expression and significantly enhanced CD11b 
surface expression. To our knowledge, this is the first 
study linking MRP4/ABCC4 to cell differentiation in a 
LSC population. 
Furthermore, we showed in vivo that the 
administration of rolipram (PDE4 inhibitor) with 
probenecid (MRP inhibitor) decreased tumor growth, 
which induced cytostasis and apoptosis. Consistent with 
this pharmacological approach, similar results were 
obtained when MRP4 was silenced by shRNA. These 
findings bring up the question why the in vivo MRP4/
ABCC4 inhibition caused cell death if there are living 
cells that express no MRP4/ABCC4. However, in analogy, 
it was shown that although most cells do not express 
Bcr-Abl, its blockade induces apoptosis in Bcr-Abl 
addicted leukemias. Thus, Bcr-Abl expression causes the 
accumulation of pro-apoptotic signals that are released by 
Bcr-Abl inhibition [31,32]. Similarly, in the present study 
MRP4/ABCC4 blockade increased cAMP levels resulting 
in cell cycle arrest and apoptosis.
The signaling pathway mediated by cAMP has 
emerged as a key regulator of blood cell proliferation, 
differentiation, and apoptosis in malignant cell populations 
[33]. While cAMP induces monocytic differentiation of 
HL-60 cells it triggers apoptosis in normal and leukemic 
thymocytes and in the myeloid leukemia cell line IPC-81 
[6,34]. Thus, the relative balance between growth arrest, 
apoptosis and differentiation apparently depends on cAMP 
levels and the cellular context. Besides, differentiation 
and apoptosis can be triggered either independently or 
combined. We previously reported that increased cAMP 
levels induce differentiation in AML cell lines [13]. In 
the present work we show that cyclic nucleotide elevation 
also favored differentiation in LSCs, although it enhanced 
apoptosis in vivo. The distinct biological responses may 
be attributable to the different experimental models used 
in this study, in vitro versus in vivo. Furthermore, the 
fact that apoptosis could have been preceded by early 
differentiation in mice cannot be excluded. 
The present study provides direct evidence in 
vivo and in vitro that MRP4/ABCC4 is involved in the 
regulation of LSCs differentiation as well as in tumor 
growth and apoptosis. In addition, clinical studies 
showed that MRP4/ABCC4 is highly expressed in blast 
cells of childhood and adult AML and higher levels 
of this transporter were observed in less differentiated 
AML subtypes [10,35]. Thus, our study, supported by 
these previous reports using patient samples, contributes 
to validate MRP4/ABCC4 as a new target for AML 
treatment. 
Just recently, a considerable body of evidence 
indicates that MRP4/ABCC4 is implicated in the 
development of cancer, supporting its role as a novel 
therapeutic target [5,36]. Thus, MRP4/ABCC4 inhibition 
should be considered as a new alternative strategy for 
cancer treatment, either alone or in combination with 
chemotherapeutic drugs. To date, no pharmacological 
inhibitors have been identified that exclusively target 
Oncotarget9317www.impactjournals.com/oncotarget
MRP4/ABCC4. Therefore, therapeutic targeting of this 
transporter will require the design of potent and specific 
novel compounds than those available. On the other hand, 
a promising emerging technology to inhibit MRP4/ABCC4 
is gene silencing using small interfering RNAs, including 
shRNA [37]. At the present time, for efficient delivery and 
stable knockdown of target genes in hematopoietic cells, 
retroviral vectors are an attractive tool [38]. In our study, a 
retroviral vector for MRP4/ABCC4 stable knockdown was 
successfully used. However, further studies are necessary 
to examine delivery conditions, biosafety and clinical 
applicability of shRNA as a biomedical tool in leukemia 
treatment.
METHODS
Animals
Six-week-old female nude (nu/nu, University of La 
Plata Animal Facility) mice were used. All animal care and 
experimental procedures complied with the Institutional 
guidelines and the United Kingdom Coordinating 
Committee on Cancer Research Guidelines for the Welfare 
of Animals in Experimental Neoplasia [39,40].
Cell culture, sorting and cell differentiation
Human U937 and KG-1a leukemia cells were 
cultured at 37°C in a humidified atmosphere with 5% CO2 
in RPMI 1640 or IMDM, respectively, containing 10% 
FCS (Invitrogen).
Fluorescent-activated cell sorting (FACS) was 
performed using standard protocols. Briefly, cells were 
incubated with mouse anti-human CD34-PE and mouse 
anti-human CD38-PECy5 (Beckman Coulter) for 30 min 
at 4°C, washed twice in PBS, analyzed and sorted using 
an Epics Altra Cell Sorter Flow Cytometer (Beckman 
Coulter). Gating on forward and side light scatter was used 
to exclude dead cells and debris. 
 In order to evaluate differentiation of the LSC 
population, after sorting CD34+CD38- cells were cultured 
in GBGM (Clear Cell Technologies) 10% FCS and treated 
with 10 µM forskolin (Sigma-Aldrich) and 50 µM MK-
571 (Sigma-Aldrich) for 48 h. 
In vivo experiments
Pharmacologic approach
The U937 cell suspension (10 x106 cells) in 
RPMI 1640 medium was subcutaneously injected into 
congenitally athymic nude mice on a Swiss background 
(N: NIH(S)-nu) from La Plata University. When tumors 
were palpable the animals were randomly assigned 
to four groups and intraperitonelly injected every 2 
days with rolipram (R, phosphodiesterase 4 inhibitor, 
1.5 mg/kg), probenecid (P, MRP inhibitor, 50 mg/kg), 
rolipram+probenecid (R+P) or with vehicle (control, 
DMSO, 0.15 ml/kg) for 16 days. 
Molecular approach
This experiment was performed with U937 cells 
expressing short hairpin RNA (shRNA) against MRP4 
(U937-shMRP4) or scrambled shRNA (U937-scramble) as 
previously reported [13]. Swiss nu/nu mice were injected 
with 10 x106 cells of U937-shMRP4 or U937-scramble. 
A third group of mice carrying U937-scramble tumor was 
treated every 2 days with rolipram+probenecid (R+P, 1.5 
mg/kg and 50 mg/kg, respectively) for 13 days.
In both experiments, tumors were measured using a 
Vernier Caliper and tumor volumes were calculated with 
the formula 4 x 3-1 x π x minor radius2 x major radius [41]. 
At the end of the experiments, animals were euthanized, 
and tumor samples removed and frozen at -80ºC for 
western blots or formalin-fixed for immunohistochemistry 
studies.
Morphological studies
The morphological features of both tumor 
parenchyma (cellular type, grade of differentiation and 
growth pattern) and stroma (blood vessels, fibrosis and 
inflammatory infiltrate) were evaluated in hematoxylin-
eosin (H&E) stained slides. Mitosis and apoptosis were 
counted in a 5 μ H&E stained sections by direct evaluation 
of 10 and 15 high power fields (HPF), respectively, using 
600 x magnification, and expressed as the mean ± SEM 
of the percentage of the ratios between the total number 
of events (mitosis or apoptosis) and the total cell number 
per HPF. Mitotic figures were identified morphologically 
by the condensed ‘‘hairy’’ aspect of the chromosomes. 
Apoptosis was evaluated by identifying an eosinophilic 
cytoplasm, cell shrinkage with condensation, peripheral 
clumping or fragmentation of nuclear chromatin and by 
the presence of apoptotic bodies [42]. In selected tumor 
sections apoptosis was determined by TUNEL [terminal 
deoxynucleotidyltransferasa (TdT)-mediated dUTP biotin 
nick end labeling-technique] following manufacturer’s 
instructions (Apoptag® peroxidase in situ apoptosis 
detection kit, Merck Millipore, MA). 
Immunohistochemistry
Formalin-fixed, paraffin-embedded tumors 
were incubated with cyclin D1 (1:100, Santa Cruz 
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Biotechnology, CA) or Bax (1:50 Santa Cruz) antibodies 
using the avidin-biotin-peroxidase complex technique 
(Vectastain Elite ABC kit, Vector Laboratories, CA). The 
reactions were developed with 3-3’diaminobenzidine 
(DAB) as described [43]. After immunohistochemistry, 
the specimens were lightly counterstained with 10% 
hematoxylin, dehydrated, and mounted.
Isolation of membrane vesicles from U937 cell line
According to El-Sheikh et al [44], cells were 
harvested by centrifugation and the pellets resuspended 
in ice-cold homogenization buffer [0.5 mM sodium 
phosphate, 0.1 mM EDTA, pH 7.4] supplemented with 
protease inhibitors and shaken at 4°C for 60 min. Lysed 
cells were centrifuged at 4°C at 100.000g for 30 min, and 
the pellets were homogenized in ice-cold TS buffer [10 
mM Tris-HEPES and 250 mM sucrose, pH 7.4] using a 
tight fitting Dounce homogenizer for 30 strokes. After 
centrifugation at 500g at 4°C for 20 min, the supernatant 
was centrifuged 4°C at 100.000g for 60 min. The resulting 
pellet was resuspended in TS buffer and passed through a 
27-gauge needle 30 times. Aliquots of crude membrane 
vesicles were frozen in liquid nitrogen, and stored at -80°C 
until assayed. Protein concentration was determined by a 
Bio-Rad protein assay kit following the manufacturer’s 
instructions.
Western Blot Assay
Isolated tumors were homogenized with a polytron 
to obtain total fractions for Western Blot as previously 
described [45]. Similar amounts of protein extracts, 
as determined by Lowry, were loaded into each lane, 
separated by SDS-polyacrylamide gel and transferred 
to nitrocellulose membranes. The residual binding sites 
were blocked with 5% non-fat powdered milk in PBS 
containing 0.05% Tween 20, and membranes were 
incubated in PBS containing 0.05% Tween 20 with 
antibodies to p21 (1:300), Caspase-3 (1:1500) (Santa 
Cruz Biotechnology, Dallas, TX), MRP4 (1/50, Thermo 
Fisher Scientific, Waltham, MA) and α-tubulin (1:5000, 
Cell signaling Technology, Beverly, CA) overnight at 4 
ºC. All subsequent washes were performed with the same 
buffer. Reactivity was developed using an anti-rabbit or 
anti-mouse polyclonal antibody linked to horseradish 
peroxidase (Vector) and developed by enhanced 
chemiluminescence (ECL) following the manufacturer’s 
instructions (Amersham, GE Healthcare Lifesciences, 
Pittsburgh, PA). 
Flow cytometry
The characterization of the LSC population 
and its differentiation was evaluated by direct 
immunofluorescence staining using different combination 
of the following monoclonal antibodies: CD34-FITC, 
CD34-PE, CD38-PECy5, CD123-PE, CD11b-PE 
(Beckman Coulter). Mouse IgG antibodies were used as 
isotype controls. 
MRP4/ABCC4 protein expression was detected by 
indirect immunofluorescence staining using the affinity 
purify polyclonal anti-human MRP4 antibody (1/50) [46]. 
The secondary antibody used in 1/200 dilution was goat 
anti-rabbit AlexaFluor 488 (Invitrogen). Incubations with 
antibodies were performed in PBS 2% FCS for 45 min 
at 4°C. Cells were washed twice with PBS 4% FCS and 
resuspended in PBS. Incubation without MRP4 antibody 
was performed as a negative control.
Data were acquired using a CyAn ADP Flow 
Cytometer (DakoCytomation, Beckman Coulter) and 
analysed using FlowJo software (Treestar).
cAMP assay
Cells were resuspended in RPMI 1640 medium at a 
density of 1 x 106 cells/ml and exposed to 25 µM forskolin 
and 1 mM 3-isobutyl-1-methylxanthine at different time 
points as indicated in the corresponding figure legend. 
Following centrifugation for 3 min at 3000 g at 4°C, 1 ml 
ethanol was added to supernantants (extracellular cAMP) 
and pellets (intracellular cAMP). Ethanol was dried and 
residues resuspended in 50 mM Tris–HCl, pH 7.4, 0.1% 
BSA for further cAMP determination. Cyclic AMP content 
was determined by competitive radio-binding assay for 
PKA using [3H]cAMP, as previously described [47]. 
The standard curve was performed using eight cAMP 
concentrations ranging from 0.1 to 90 pmol. Duplicate 
samples in at least three independent experiments were 
analyzed.
Statistical analysis
Statistics were performed using GraphPad Prism 
5.0 via an unpaired t test or one-way analysis of variance 
(ANOVA) followed by Bonferroni’s comparison test. 
Differences were considered to be significant at p<0.05.
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